Pharmacogenetics 11:6639, PMID: 11692074 Fernandes AP, Holmgren A (2004) Glutaredoxins: glutathione-dependent redox enzymes with functions far beyond a simple thioredoxin backup system
Legumes dont even have that much protein, nor all the essential amino acids
Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est
If patients present with symptoms such as upper abdominal pain, nausea, or vomiting, prompt imaging evaluation should be conducted
72 Autism and attention deficit hyperactivity disorder (ADHD) The two main symptoms of autism spectrum disorder (ASD) are a deficit in social communication and/or interaction and repetitive behaviours and/or restricted interests
and a plan